New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
09
10
2020
accepted:
13
05
2021
revised:
26
04
2021
pubmed:
27
5
2021
medline:
15
12
2021
entrez:
26
5
2021
Statut:
ppublish
Résumé
The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. In total, 2298 women (≥45 years, invasive ductal carcinoma ≤3.5 cm, cN0-N1) were randomised. We investigated the impact of tumour size, grade, ER, PgR, HER2 and lymph node status on local recurrence-free survival, and of local recurrence on distant relapse and mortality. We analysed the predictive factors for recommending supplemental EBRT after TARGIT-IORT as part of the risk-adapted approach, using regression modelling. Non-breast cancer mortality was compared between TARGIT-IORT plus EBRT vs. EBRT. Local recurrence-free survival was no different between TARGIT-IORT and EBRT, in every tumour subgroup. Unlike in the EBRT arm, local recurrence in the TARGIT-IORT arm was not a predictor of a higher risk of distant relapse or death. Our new predictive tool for recommending supplemental EBRT after TARGIT-IORT is at https://targit.org.uk/addrt . Non-breast cancer mortality was significantly lower in the TARGIT-IORT arm, even when patients received supplemental EBRT, HR 0.38 (95% CI 0.17-0.88) P = 0.0091. TARGIT-IORT is as effective as EBRT in all subgroups. Local recurrence after TARGIT-IORT, unlike after EBRT, has a good prognosis. TARGIT-IORT might have a beneficial abscopal effect. ISRCTN34086741 (21/7/2004), NCT00983684 (24/9/2009).
Sections du résumé
BACKGROUND
The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses.
METHODS
In total, 2298 women (≥45 years, invasive ductal carcinoma ≤3.5 cm, cN0-N1) were randomised. We investigated the impact of tumour size, grade, ER, PgR, HER2 and lymph node status on local recurrence-free survival, and of local recurrence on distant relapse and mortality. We analysed the predictive factors for recommending supplemental EBRT after TARGIT-IORT as part of the risk-adapted approach, using regression modelling. Non-breast cancer mortality was compared between TARGIT-IORT plus EBRT vs. EBRT.
RESULTS
Local recurrence-free survival was no different between TARGIT-IORT and EBRT, in every tumour subgroup. Unlike in the EBRT arm, local recurrence in the TARGIT-IORT arm was not a predictor of a higher risk of distant relapse or death. Our new predictive tool for recommending supplemental EBRT after TARGIT-IORT is at https://targit.org.uk/addrt . Non-breast cancer mortality was significantly lower in the TARGIT-IORT arm, even when patients received supplemental EBRT, HR 0.38 (95% CI 0.17-0.88) P = 0.0091.
CONCLUSION
TARGIT-IORT is as effective as EBRT in all subgroups. Local recurrence after TARGIT-IORT, unlike after EBRT, has a good prognosis. TARGIT-IORT might have a beneficial abscopal effect.
TRIAL REGISTRATION
ISRCTN34086741 (21/7/2004), NCT00983684 (24/9/2009).
Identifiants
pubmed: 34035435
doi: 10.1038/s41416-021-01440-8
pii: 10.1038/s41416-021-01440-8
pmc: PMC8329051
doi:
Banques de données
ClinicalTrials.gov
['NCT00983684']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-389Subventions
Organisme : Department of Health
ID : 14/49/13
Pays : United Kingdom
Organisme : Department of Health
ID : 07/60/49
Pays : United Kingdom
Organisme : Department of Health
ID : 10/104/07
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
Int J Mol Sci. 2019 May 02;20(9):
pubmed: 31052488
Int J Mol Sci. 2019 Jun 29;20(13):
pubmed: 31261963
Lancet. 1997 Jan 18;349(9046):208
pubmed: 9111565
Ann Oncol. 2015 Dec;26(12):2505-6
pubmed: 26467471
N Engl J Med. 2013 Jun 27;368(26):2526-7
pubmed: 23802528
Strahlenther Onkol. 2017 Jan;193(1):62-69
pubmed: 27858093
Br J Cancer. 1996 Sep;74(5):820-4
pubmed: 8795588
Lancet. 2010 Jul 10;376(9735):91-102
pubmed: 20570343
Ann Oncol. 2001 Aug;12(8):1075-80
pubmed: 11583188
Health Technol Assess. 2016 Sep;20(73):1-188
pubmed: 27689969
BMJ. 2020 Aug 19;370:m2836
pubmed: 32816842
J Biomed Phys Eng. 2020 Aug 01;10(4):537-542
pubmed: 32802801
Clin Cancer Res. 2008 Mar 1;14(5):1325-32
pubmed: 18316551
Eur J Surg Oncol. 2002 Jun;28(4):447-54
pubmed: 12099658
J Neurooncol. 2019 Nov;145(2):391-397
pubmed: 31654248
Br J Cancer. 2021 Apr;124(9):1469-1474
pubmed: 33531693
JAMA Oncol. 2020 Jul 1;6(7):e200249
pubmed: 32239210
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33946741
Trends Immunol. 2018 Aug;39(8):644-655
pubmed: 30001871
PLoS One. 2014 Jan 22;9(1):e84991
pubmed: 24465461